Suppr超能文献

英国非处方大麻二酚产品分析。

An Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom.

机构信息

Centre for Medicinal Cannabis, London, United Kingdom.

Cannabis Patient Advocacy & Support Services, London, United Kingdom.

出版信息

Cannabis Cannabinoid Res. 2022 Apr;7(2):207-213. doi: 10.1089/can.2019.0078. Epub 2020 Apr 1.

Abstract

Over-the-counter cannabidiol (CBD) products have seen unprecedented recent growth in the United Kingdom. However, analysis of these predominantly unregulated products from other countries tells us that they are often mislabeled or contain unlabeled and potentially dangerous chemicals. Thus, the aim of the present study was to analyze CBD oils available in the United Kingdom. Phytocannabinoids, residual solvent, and heavy metals were measured blinded in 29 widely available CBD products by an independent testing facility using high-performance liquid chromatography with diode-array detection for cannabinoids, Headspace-gas chromatography-flame ionization detector and gas chromatography-mass spectrometry for residual solvents, and inductively coupled plasma-mass spectrometry for heavy metals. The mean advertised CBD content was 4.5%, and the actual mean measured CBD content of products was 3.2% (=0.053, Mann-Whitney test). Only 11/29 (38%) products were within 10% of the advertised CBD content. Fifty five percent of products had measurable levels of the controlled substances Δ-tetrahydrocannabinol (mean content 0.04%) or cannabinol (mean content 0.01%), as well as most other phytocannabinoid compounds including cannabidiolic acid (CBDA), cannabidivarin (CBDV), and cannabidivarin acid (CBDVA). Detectable levels of N-pentane, ethanol, isopropanol, heptane, lead, and arsenic were found in many of the CBD products, but these were within acceptable levels. As demonstrated in other countries, the quality of over-the-counter CBD products in the United Kingdom can be substandard, particularly with regard to CBD content, and often contains levels of controlled substances. We recommend that these products be more strictly regulated for consumer welfare.

摘要

非处方类的大麻二酚 (CBD) 产品在英国最近出现了前所未有的增长。然而,对这些主要不受监管的来自其他国家的产品进行分析后,我们发现它们经常标签有误或含有未标注且可能有害的化学物质。因此,本研究旨在分析英国市场上的 CBD 油。一家独立检测机构使用高效液相色谱二极管阵列检测法对 29 种广泛流通的 CBD 产品进行了盲测,以检测其中的植物大麻素、残留溶剂和重金属。利用顶空-气相色谱-火焰离子化检测器和气相色谱-质谱联用仪检测残留溶剂,电感耦合等离子体质谱仪检测重金属。广告中 CBD 的平均含量为 4.5%,而产品实际测量 CBD 的平均含量为 3.2%(=0.053,Mann-Whitney 检验)。只有 11/29(38%)的产品 CBD 含量在广告含量的 10%以内。55%的产品有可测量水平的受管制物质 Δ-四氢大麻酚(平均含量 0.04%)或大麻酚(平均含量 0.01%),以及包括大麻二酚酸(CBDA)、大麻二酚(CBDV)和大麻二酚酸(CBDVA)在内的大多数其他植物大麻素化合物。许多 CBD 产品中都检测到了正戊烷、乙醇、异丙醇、庚烷、铅和砷的痕迹,但这些都在可接受的范围内。正如在其他国家所证明的那样,英国非处方 CBD 产品的质量可能不达标,尤其是 CBD 含量方面,而且往往含有受管制物质的水平。我们建议对这些产品进行更严格的监管,以保障消费者的福利。

相似文献

1
An Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom.
Cannabis Cannabinoid Res. 2022 Apr;7(2):207-213. doi: 10.1089/can.2019.0078. Epub 2020 Apr 1.
2
Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi.
J Diet Suppl. 2020;17(5):599-607. doi: 10.1080/19390211.2020.1766634. Epub 2020 May 20.
4
Combination of UV and MS/MS detection for the LC analysis of cannabidiol-rich products.
Talanta. 2020 Nov 1;219:121250. doi: 10.1016/j.talanta.2020.121250. Epub 2020 Jun 17.
5
Cannabidiol and tetrahydrocannabinol concentrations in commercially available CBD E-liquids in Switzerland.
Forensic Sci Int. 2020 May;310:110261. doi: 10.1016/j.forsciint.2020.110261. Epub 2020 Mar 20.
6
Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners.
Epilepsy Behav. 2022 Feb;127:108514. doi: 10.1016/j.yebeh.2021.108514. Epub 2022 Jan 5.
9
Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15.
Addiction. 2015 Dec;110(12):1941-50. doi: 10.1111/add.13082. Epub 2015 Sep 18.
10
Enantioseparation of chiral phytocannabinoids in medicinal cannabis.
J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Apr 15;1221:123682. doi: 10.1016/j.jchromb.2023.123682. Epub 2023 Mar 21.

引用本文的文献

3
Over the counter CBD products in Germany: an exploratory survey about consumption patterns and health related effects.
Front Pharmacol. 2025 May 21;16:1571025. doi: 10.3389/fphar.2025.1571025. eCollection 2025.
4
5
Challenges of cannabidiol determination in emulsified cosmetics and application of solid-phase extraction followed by HPLC-UV-MS/MS.
Anal Bioanal Chem. 2025 Mar;417(6):1153-1163. doi: 10.1007/s00216-024-05716-9. Epub 2025 Jan 7.
7
The attitudes, knowledge and confidence of healthcare professionals about cannabis-based products.
J Cannabis Res. 2024 Jul 24;6(1):32. doi: 10.1186/s42238-024-00242-y.
8
Does a broad-spectrum cannabidiol supplement improve performance in a 10-min cycle ergometer performance-test?
Eur J Sport Sci. 2024 Jul;24(7):870-877. doi: 10.1002/ejsc.12116. Epub 2024 May 3.
9
Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples.
Front Pharmacol. 2024 Mar 18;15:1335441. doi: 10.3389/fphar.2024.1335441. eCollection 2024.
10
Evaluation of dispensaries' cannabis flowers for accuracy of labeling of cannabinoids content.
J Cannabis Res. 2024 Mar 9;6(1):11. doi: 10.1186/s42238-024-00220-4.

本文引用的文献

1
The Trouble with CBD Oil.
Med Cannabis Cannabinoids. 2018 Jun 12;1(1):65-72. doi: 10.1159/000489287. eCollection 2018 Jun.
2
A systematic review of cannabidiol dosing in clinical populations.
Br J Clin Pharmacol. 2019 Sep;85(9):1888-1900. doi: 10.1111/bcp.14038. Epub 2019 Jul 19.
3
Cannabidiol Adverse Effects and Toxicity.
Curr Neuropharmacol. 2019;17(10):974-989. doi: 10.2174/1570159X17666190603171901.
4
Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain.
Arch Oral Biol. 2019 Aug;104:33-39. doi: 10.1016/j.archoralbio.2019.05.028. Epub 2019 May 28.
5
Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol.
J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):844-859. doi: 10.1002/jcsm.12426. Epub 2019 Apr 29.
7
Cannabinoid Ligands Targeting TRP Channels.
Front Mol Neurosci. 2019 Jan 15;11:487. doi: 10.3389/fnmol.2018.00487. eCollection 2018.
8
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans.
Front Pharmacol. 2018 Nov 26;9:1365. doi: 10.3389/fphar.2018.01365. eCollection 2018.
9
The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e-liquids.
Forensic Sci Int. 2019 Jan;294:e25-e27. doi: 10.1016/j.forsciint.2018.10.019. Epub 2018 Nov 1.
10
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验